| ²é¿´: 440 | »Ø¸´: 0 | |||
iningľ³æ (ÕýʽдÊÖ)
|
[½»Á÷]
ÈÕ±¾ÁøÉ¼»¨·Û±äÓ¦ÔÉàÏÂÆ¬¼ÁµÄ¼²²¡ÐÞÊÎ×÷ÓÃ
|
|
Ñо¿±³¾°£º ÔÚÈÕ±¾£¬ÈÕ±¾ÁøÉ¼£¨Japanese cedar£¬JC£©»¨·ÛÖ¢ÊÇÒ»ÖÖ³£¼ûµÄ±äÓ¦ÐÔ±ÇÑס£JC»¨·ÛÉàÏÂÃâÒßÖÎÁÆ£¨sublingual immunotherapy£¬SLIT£©Æ¬¼Á±»Åú×¼ÓÃÓÚJC»¨·ÛÖ¢µÄÖÎÁÆ¡£ Ñо¿Ä¿µÄ£º ÆÀ¹À5ÄêÄÚ£¨2014-2019Ä꣩£¬JC»¨·ÛSLITƬ¼ÁµÄ¼²²¡ÐÞÊÎ×÷Ó㬰üÀ¨3ÄêÁƳÌÓë2ÄêËæ·Ã¡£ Ñо¿·½·¨£º Ñо¿×ܹ²Èë×é1042Ãû5~64ËêJC»¨·ÛÖ¢»¼Õß¡£Ç°15¸öÔ¿ªÕ¹×î¼Ñ¼ÁÁ¿Ñо¿£¬Ö®ºó½«240Ãû¶ÔÕÕ×黼Õߣ¨placebo£¬P ×飩ÒÔ¼°236Ãû×î¼Ñ»îÐÔ¼ÁÁ¿×黼Õߣ¨active dose£¬A×飬5000ÈÕ±¾¹ýÃôµ¥Î»£©ÖØÐÂËæ»ú·Ö×飬·Ö±ð½ÓÊܶîÍâ18¸öÔÂÁƳÌPºÍAÖÎÁÆ£¨·Ö×éΪAA¡¢AP¡¢PA¡¢PPËÄ×飩¡£²ÉÓÃÿ¸öJC»¨·Û¼¾ÖÐÖ¢×´¸ß·åÆÚµÄ±Ç²¿Ö¢×´ºÍÒ©Îï×ÜÆÀ·Ö£¨total nasal symptom and medication score£¬TNSMS£©£¬ÆÀ¹ÀÈýÄêÁƳ̼°ÖÎÁÆÍ£Ö¹ºóÁ½Äê¹Û²ìÖл¼ÕßµÄÁÙ´²ÁÆÐ§¡£ Ñо¿½á¹û¼°½áÂÛ£º AA¡¢AP¡¢PAÈý×éTNSMS³ÊÏÖ³öÃ÷ÏÔ½µµÍ£»µ«ÊÇ£¬ AA×éÔÚÃâÒßÖÎÁƽ׶Σ¨µÚÈý¸ö»¨·Û¼¾£¬46.3%vsPP×飬P<.001£©ÒÔ¼°2ÄêËæ·Ã½×¶Î£¨µÚËĸö»¨·Û¼¾ºÍµÚÎå¸ö»¨·Û¼¾£¬·Ö±ðΪ45.3%ºÍ34.0%vsPP×飬P<.001£©ÆÀ·Ö½µµÍ¶¼Ïà¶Ô×îÃ÷ÏÔ¡£×î³£¼û²»Á¼·´Ó¦Îª¸øÒ©²¿Î»µÄÇá΢²»ÄÍÊÜ·´Ó¦¡£ JC»¨·ÛSLITƬ¼ÁÔÚÈýÄêÁƳÌÖоßÓгÖÐøµÄÁÙ´²ÁÆÐ§£¬²¢ÇÒÔÚÁƳÌÍ£Ö¹ºó¾ßÓÐÖÁÉÙ2ÄêµÄ¼²²¡ÐÞÊÎ×÷Óᣠ|
» ²ÂÄãϲ»¶
R×öÏà¹ØÍ¼Ê±±¨´í£¬²ÎÊýÖµÒâζ×Ų»Í¬µÄÐÐÊý: 91, 78
ÒѾÓÐ0È˻ظ´
µç»¯Ñ§´«¸ÐÆ÷6ÛÏ»ù¼º´¼ÐÞÊÎ×迹±äС
ÒѾÓÐ9È˻ظ´
Ñ»·ÏµÍ³ÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ291È˻ظ´
¡¶ÖйúÒ©µä¡·2020Äê°æµç×Ó°æ·ÖÏí
ÒѾÓÐ13È˻ظ´
µ÷¼ÁÇóÖú
ÒѾÓÐ0È˻ظ´
ÇóÖú£ºÖ´ÒµÖÐҩʦÊÓÆµ±¸¿¼×ÊÁÏ
ÒѾÓÐ0È˻ظ´
ÇóÖú£ºÖ´ÒµÖÐҩʦÊÓÆµ±¸¿¼×ÊÁÏ
ÒѾÓÐ0È˻ظ´
²åÎÄÏ×
ÒѾÓÐ1È˻ظ´













»Ø¸´´ËÂ¥
5